One Oncology

START and OneOncology launch 3 new early-phase trial sites, expanding access to new cancer research in community oncology settings.

For Bladder Cancer Awareness Month, Jahan Aghalar, MD, discussed the latest advancements in treating patients with bladder cancer along with which targets have helped to push the field forward.

For Brain Cancer Awareness Month, Charles Redfern, MD, discussed the biggest technological changes to treatment for adult patients with brain cancer and how holistic treatment remains important for treating this challenging disease.

Clinically meaningful differentiation across efficacy measures were seen in patients administered domvanalimb in combination with zimberleimab or etrumadenant vs zimberelimab monotherapy.

In an interview with Targeted Oncology, Lee Schwartzberg, MD, further discusses the findings of KEYNOTE-522 and pembrolizumab in patients with triple negative breast cancer.

The community oncology organization, Tennessee Oncology, reportedly saved Medicare $5 million between 2019 and 2020.

In an interview with Targeted Oncology™, Statish Shah, MD, the medical director of Gettysburg Cancer Center, discusses the OneOncology partnership in more detail and how it will benefit patients. 

Gettysburg Cancer Center, with clinics in Gettysburg and Hanover, PA, will join OneOncology, the national platform for independent community oncology practices, OneOncology announced.

The Center for Cancer and Blood Disorders, which serves 12,000 patients a year in North Texas, is now offering their patients and caregivers the COVID-19 vaccine.

For World Cancer Day, Jeff Patton, MD, discusses COVID-19’s impact on cancer treatment and testing in an interview with Targeted Oncology.

OneOncology announced the creation of OneOncology Research Network, which is a national non-exclusive clinical trial site management organization.